- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05550545
Infant RSV Infections and Health-related Quality of Life of Families (ResQFamily)
ResQ Family: Impact of Respiratory Syncytial Virus (RSV) Hospitalisation on Quality of Life of Families - A Multi-Country Study
Until today, there is only little information available on how severe RSV infection leading to hospitalisation of the infant impacts the quality of life of affected families. For the ResQ Family project, an online questionnaire will be used to survey parents or caregivers of children up to 24 months currently or recently hospitalised (length of hospital stay of at least 12 hours and hospital admission no longer than 4 weeks ago) due to RSV infection.
The aim of the ResQ Family project is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public. The project will run until June 2024. Data collection will take place during the RSV season from fall 2022 to spring 2023 in four European countries: France, Germany, Italy, and Sweden.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Respiratory Syncytial Virus (RSV) is a very contagious virus and the most common cause of lower respiratory tract infections such as bronchiolitis and pneumonia in infants. By the age of two years, nearly all infants will be infected with RSV at least once. Globally, it is a leading cause of hospitalisations among young infants with approximately 33 million cases of acute lower respiratory infections causing more than three million hospitalisations each year in children younger than 5 years. While most RSV cases are mild, one can't predict which infants could get seriously ill and end up in hospital. This is because the course of the disease is unpredictable.
When the RSV infection of the child is severe and associated with hospitalisation, it may lead to intensive care unit admissions with use of supportive care such as mechanical ventilation. It may further result in long-term complications such as recurrent wheezing, reduced pulmonary function and asthma. Moreover, RSV-related hospitalisations can be associated with a significant burden on the entire family, causing considerable stress and increased loss of work productivity. Currently, there is a lack of adequate information on how severe RSV infection leading to hospitalisation of infants (< 2 years) impacts the quality of life of affected families.
To close this knowledge gap, the ResQ Family research project was initiated: ResQ Family: Impact of Respiratory Syncytial Virus (RSV) hospitalisation on Quality of life of Families - a multi-country study. The project runs from December 2021 until June 2024 and covers four European countries: France, Germany, Italy and Sweden. Data will be collected between autumn 2022 and spring 2023, corresponding to a typical RSV season duration in temperate countries in the northern hemisphere.
The aim of the ResQ Family study is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public.
An online questionnaire will be used to ask parents and caregivers of children experiencing (or having recently experienced) hospitalisation due to RSV infection to share their experiences and a follow-up will take place after six weeks. The study focuses on children up to 24 months with a hospital stay due to RSV infection of at least 12 hours in total. The hospital admission should not be longer than 4 weeks ago.
Experienced researchers and health care professionals renowned in the field of RSV as well as parent/patient representatives support the project as part of an external scientific advisory board and a project expert group.
EFCNI received a research grant from Sanofi in support of this independent study.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Christina Tischer, PhD
- Phone Number: +49 (0)89 / 89083260
- Email: research@efcni.org
Study Contact Backup
- Name: Christina Tischer, PhD
- Phone Number: +49 (0)89 / 89083260
- Email: christina.tischer@efcni.org
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 81379
- Recruiting
- EFCNI
-
Contact:
- Christina Tischer, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Parents or caregivers of children younger than 24 months of age with a hospitalisation for at least 12 hours due to RSV infection
- Living in Germany, Sweden, Italy or France
- The diagnosis can either be confirmed by a test such as ELISA/IFT/PCR from nasal secretion, sputum or throat swab or by a doctor based on specific symptoms typically during the RSV season
- They can be reached during or after hospitalisation, ideally right after the discharge from hospital but at least within four weeks after hospital admission
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Parents/caregivers of RSV-infected infants
|
Please note that this is an observational study; not applicable
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related quality of life of parents/caregivers and family functioning
Time Frame: Baseline (Day 0)
|
The 36-item version of the Pediatric Quality of Life Inventory Family Impact Module (PedsQLTM FIM) was used to assess the quality of life of parents/caregiver when the child was infected and hospitalized for RSV.
It composes of six scales measuring parent self-reported functioning: 1) Physical functioning (6 items), 2) Emotional functioning (5 items), 3) Social functioning (4 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and in addition two scales measuring parent-reported family functioning: 7) Daily activities (3 items) and 8) Family relationships (5 items).
Each of the items have five Likert response options: 0 = never a problem, 1 = almost never, 2 = sometimes, 3 = often, 4= almost always.
Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).
|
Baseline (Day 0)
|
Health-related quality of life of parents/caregivers and family functioning
Time Frame: 6 weeks follow-up (Week 6)
|
The 36-item version of the Pediatric Quality of Life Inventory Family Impact Module (PedsQLTM FIM) was used to assess the quality of life of parents/caregiver when the child was infected and hospitalized for RSV.
It composes of six scales measuring parent self-reported functioning: 1) Physical functioning (6 items), 2) Emotional functioning (5 items), 3) Social functioning (4 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and in addition two scales measuring parent-reported family functioning: 7) Daily activities (3 items) and 8) Family relationships (5 items).
Each of the items have five Likert response options: 0 = never a problem, 1 = almost never, 2 = sometimes, 3 = often, 4= almost always.
Items are reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better functioning (less negative impact).
|
6 weeks follow-up (Week 6)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Socio-demographics
Time Frame: Baseline (Day 0)
|
Parental self-report - self-designed questions: socio-demographics (parents/caregiver), risk factors (smoking, allergic diseases), place of living, birth weight (child, categories and in grams), RSV prophylaxis, breastfeeding, day-care attendance
|
Baseline (Day 0)
|
Child's co-morbidities
Time Frame: Baseline (Day 0)
|
Parental self-report - self-designed questions: pre-existing health-conditions before or apart from the current recent hospitalisation due to RSV
|
Baseline (Day 0)
|
Child's symptoms during RSV infection and hospitalisation
Time Frame: Baseline (Day 0)
|
Parental self-report - self-designed questions: RSV diagnose (child), duration of hospitalisation (in days), supportive care measure in hospital, feelings (parents) in relation to the hospitalisation of the child (categories), presence with the child receiving special/intensive care, duration of symptoms (up to 7 days and more), child's behaviour (categories), worry of parents/caregiver about symptoms (categories) |
Baseline (Day 0)
|
Child's symptoms after RSV infection and hospitalisation
Time Frame: 6 weeks follow-up (Week 6)
|
Parental self-report - self-designed questions: Duration of symptoms (in days), child's behaviour, worry of parents/caregiver about symptoms (categories) |
6 weeks follow-up (Week 6)
|
Other
Time Frame: Baseline (Day 0)
|
Parental self-report - self-designed questions: Health literacy, support structures, loss of work productivity (in hours), subjective assessment of parental health status (categories: 1=very bad to 10 = excellent), overall impact of the entire RSV episode (open question) |
Baseline (Day 0)
|
Other
Time Frame: 6 weeks follow-up (Week 6)
|
Parental self-report - self-designed questions: Loss of work productivity (in hours), subjective assessment of parental health status (categories: 1=very bad to 10 = excellent), overall impact of the entire RSV episode (open question) |
6 weeks follow-up (Week 6)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Johanna Kostenzer, PhD, European Foundation for the Care of Newborn Infants
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-3307
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
-
Institute of Oncology LjubljanaUnknownHealth-related Quality of LifeSlovenia
Clinical Trials on cohort study
-
Vanderbilt University Medical CenterRecruitingCovid19 | Pulmonary Fibrosis | Sars-CoV-2 Infection | COVID-19 Acute Respiratory Distress Syndrome | Dyspnea Caused by 2019-nCoVUnited States
-
Hannover Medical SchoolUnknownCommunity Acquired PneumoniaGermany
-
Samsung Medical CenterCytoGen, Inc.; UNIST (Ulsan National Institute of Science and Technology)Active, not recruitingNSCLC Stage IV | NSCLC Stage IIIBKorea, Republic of
-
Lawson Health Research InstituteRecruitingKnee Osteoarthritis | Hip OsteoarthritisCanada
-
Alopexx Vaccine, LLCCompletedPNAG-expressing Pathogenic Microbes VaccineUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Sorbonne... and other collaboratorsNot yet recruitingImmune System Diseases | Lymphoma | Lymphoproliferative Disorders | Autoimmune Diseases | Inflammation | Myelodysplastic Syndromes | Hematologic Diseases | Leukemia | Myeloproliferative Disorders | Myelodysplastic-Myeloproliferative Diseases | Monoclonal Gammopathy of Undetermined Significance | Autoinflammatory... and other conditions
-
Temple UniversityNational Institute on Minority Health and Health Disparities (NIMHD); National...Active, not recruitingSmoking | Lung Diseases | SleepUnited States
-
Vrije Universiteit BrusselUniversity Ghent; Research Foundation FlandersNot yet recruiting
-
Children's Hospital of Fudan UniversityCompletedVLBW - Very Low Birth Weight InfantChina
-
Vestre VikenHF Kongsberg SykehusUnknownDevelopmental Dysplasia of the Hip (DDH)Norway